A single medicine can travel through three layers of packaging before it reaches a patient: the blister or bottle, the carton, and the shipping case. Each layer has its own labeling rules, and each carries some of the same information: the product name, strength, batch number, expiry date, and identifiers.
That overlap is where the risk sits. When a label change reaches the carton but not the blister, or the case but not the carton, the product ships inconsistent. This guide explains what each packaging level is, what it must carry under EU and US rules, and how to keep all levels aligned.
Scope: this guide focuses on prescription medicines for human use. If you make over-the-counter (OTC) products, see the section near the end on how the rules differ.
The Three Levels of Pharmaceutical Packaging
The US and EU describe the same levels with different terms.
In EU law, outer packaging is simply the packaging into which the immediate packaging is placed. Where a product has no outer packaging, the requirements for the outer packaging apply to the immediate packaging instead.
Secondary Packaging: What the Outer Carton Must Carry
In the EU, Directive 2001/83/EC sets out the labeling particulars in Title V. Article 54 lists what must appear on the outer packaging, including:
- The name of the medicine, with strength and pharmaceutical form, and the international non-proprietary name (INN) where one exists
- The active substances and excipients with a known effect
- Pharmaceutical form and contents (by weight, volume, or number of doses)
- Method and, if necessary, route of administration, with space to indicate the prescribed dose
- A warning to keep the product out of the sight and reach of children, and any other special warnings
- The expiry date and any special storage conditions
- Disposal precautions where relevant
- The name and address of the marketing authorization holder
- The marketing authorization number and the batch number
The carton is also where most EU-specific features sit: Braille, safety features, and any national blue box information (all covered below).
In the US, 21 CFR Part 201 sets the content requirements for drug labeling, which apply to both the container label and the carton. The carton typically carries the full required labeling, and Part 201 provides relief in some cases where a container is too small to carry everything.
Primary Packaging: What Blisters and Small Containers Must Carry
Primary packaging usually has the least space, so EU law allows a reduced set of particulars in two situations (Article 55):
Blister packs placed in a compliant outer carton must carry at least:
- The name of the medicine (with INN where applicable)
- The name of the marketing authorization holder
- The expiry date
- The batch number
Small immediate packaging units, where the full particulars can't fit, must carry at least:
- The name of the medicine and, if necessary, the route of administration
- The method of administration
- The expiry date and batch number
- The contents by weight, volume, or unit
Where a primary pack isn't placed in an outer carton, the full Article 54 particulars apply to it directly.
Across all levels, particulars must be easily legible, clearly comprehensible, and indelible, and must appear in the official language or languages of the Member State where the product is placed on the market.
Tertiary Packaging: Shippers and Cases
EU labeling law focuses on the outer and immediate packaging. Shipper case labels are governed mainly by distribution requirements, trading partner specifications, and GS1 standards rather than by Title V particulars.
In the US, tertiary packaging matters more because of serialization (next section). And across both regions, case labels still carry product, batch, and expiry information that must match the packs inside.
Barcodes and Serialization by Level
This is where requirements differ most by packaging level.
EU safety features. Under Article 54a and Delegated Regulation (EU) 2016/161, most prescription medicines must carry a unique identifier, a 2D Data Matrix encoding the product code, serial number, batch number, and expiry date, plus an anti-tampering device on the outer packaging.
US linear barcode. Most prescription drug labels must carry a linear barcode containing the NDC under 21 CFR 201.25.
US DSCSA product identifier. Under the Drug Supply Chain Security Act, the smallest individual saleable unit, called the "package," generally needs a 2D Data Matrix barcode, in addition to the linear barcode required under 201.25. FDA's product identifier guidance sets out the details and the cases where a 2D barcode may not be required. Homogeneous cases, meaning shipper cases containing a single product, lot, and NDC, also need a product identifier.
What's changing: FDA's final rule moving to a 12-digit NDC format takes effect in 2033, and it will affect every packaging level that carries an NDC. We cover the details in SPL Is Changing: The Text Risk Pharma Teams Underestimate. For the wider barcode picture, see our GS1 Sunrise 2027 guide.
Braille, Blue Box, and Language Requirements (EU)
Braille. The name of the medicine must appear in Braille on the outer packaging (Article 56a).
Blue box. Member States can require additional national information on the outer packaging, such as the legal supply status and price or reimbursement details, under Article 57. The European Commission's packaging guideline explains how this works for centrally authorized products.
Languages. Every market needs the particulars in its official language or languages. Multi-language packs are common, and each language version is another variant that has to stay consistent with the approved text.
What's Changing
The EU Pharma Package. The EU's new pharmaceutical legislation will restructure the labeling rules in Directive 2001/83/EC and allow Member States to accept electronic-only leaflets in some cases. It's still pending formal adoption. Our ePI and dual-channel PIL guide covers the shift to electronic product information.
PPWR carve-outs for medicines. The EU's Packaging and Packaging Waste Regulation excludes the immediate packaging of medicinal products from certain requirements, notably recycled content targets, and extends that to outer packaging where it must meet specific requirements to preserve product quality. Other PPWR obligations may still apply, so check our PPWR compliance guide.
DSCSA timelines. Most trading partners are now subject to DSCSA's enhanced requirements. FDA has extended the exemption for small dispensers, such as independent pharmacies, to November 27, 2027. That doesn't change manufacturers' labeling obligations, but it's useful context: the serialized data on your packages and cases is increasingly being scanned and checked downstream.
Where Errors Happen: Consistency Between Levels
The most common packaging-level error isn't a missing requirement. It's inconsistency. The same information appears in full on the carton, in reduced form on the blister, and again on the case, and a change doesn't reach all three.
Typical examples:
- A batch or expiry format changed on the carton but not on the blister foil
- A strength or product name updated in one language on a multi-language pack but not in another
- An NDC or product code updated in the carton artwork while the case label still uses the old one
- A barcode that decodes to data that doesn't match the human-readable text printed next to it
Each packaging level is often designed and approved separately, sometimes by different teams or vendors. Checking each one on its own won't catch a mismatch between them. The fix is to verify every level against the same approved master, and against each other. The same principle applies to device labeling, as we explain in our UDI Labeling Requirements guide, and it depends on solid document version control.
If You Make OTC Products
Most of this guide applies to OTC medicines too, but four differences matter:
Drug Facts label (US). OTC drugs must use FDA's standardized Drug Facts format under 21 CFR 201.66, with a fixed order of headings, set content, and minimum type sizes. It's the biggest labeling difference from prescription products, and a common source of layout errors.
Tamper-evident packaging (US). Most OTC products must be sold in tamper-evident packaging, with a label statement describing the tamper-evident feature, under 21 CFR 211.132.
Serialization mostly doesn't apply. DSCSA covers prescription drugs, so OTC packages generally don't need the DSCSA product identifier. The linear NDC barcode requirement is also narrower for OTC products, applying mainly to those commonly used in hospitals.
EU safety features are the exception, not the rule. OTC medicines are exempt from the unique identifier and anti-tampering device unless specifically listed as at risk of falsification in Delegated Regulation 2016/161.
Summary: What to Check at Each Level
Primary (blister, vial, bottle)
☐ Minimum required particulars present for the pack type
☐ Name, strength, batch, and expiry match the carton exactly
☐ Language versions consistent with the approved text
Secondary (carton)
☐ Full required particulars present (Article 54 / Part 201)
☐ Braille, safety features, and blue box where applicable
☐ Barcodes decode correctly and match the human-readable text
Tertiary (case)
☐ Product, batch, and expiry match the packs inside
☐ Product identifier present where required (DSCSA homogeneous cases)
Across all levels
☐ Every level verified against the same approved master
☐ Levels compared against each other after every change
For the full step-by-step process, use our Artwork Approval Process Checklist. For current FDA and EMA content requirements, see our Pharmaceutical Labeling Requirements guide.
Content Compare verifies every packaging level, from blister to carton to case, against your approved master in a single session, including text, graphics, barcodes, and Braille. See how it works on your own artwork.